UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 2.525

Sortiert nach

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e14

2024

Link zum Volltext

Verfügbarkeit prüfen

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e4-e5

2024

Link zum Volltext

Verfügbarkeit prüfen

A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation

International journal of radiation oncology, biology, physics, 2024-01, Vol.118 (1), p.e13-e14

2024

Link zum Volltext

Verfügbarkeit prüfen

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9158-TPS9158

2023

Link zum Volltext

Verfügbarkeit prüfen

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC)

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.9007-9007

2023

Link zum Volltext

Verfügbarkeit prüfen

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.TPS9144-TPS9144

2023

Link zum Volltext

Verfügbarkeit prüfen

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Journal of thoracic oncology, 2023-11, Vol.18 (11), p.S117-S118

2023

Link zum Volltext

Verfügbarkeit prüfen

Abstract LBA038: KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.LBA038-LBA038

2021

Link zum Volltext

Verfügbarkeit prüfen

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

Molecular cancer therapeutics, 2021-12, Vol.20 (12_Supplement), p.P124-P124

2021

Link zum Volltext

Verfügbarkeit prüfen

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Cancer discovery, 2022-06, Vol.12 (6), p.1500-1517

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT048-CT048

2023

Link zum Volltext

Verfügbarkeit prüfen

EN1-5. KontRASt-01 : A Phase Ib/II, dose-escalation study of JDQ443 in patients with KRAS G12C+ solid tumors

Japanese Journal of Lung Cancer, 2022-11, Vol.62 (6), p.559-559

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.CT033-CT033

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.4026-4026

2022

Link zum Volltext

Verfügbarkeit prüfen

SU‐GG‐I‐121: JDQE: A User‐Friendly ImageJ Plugin for DQE Calculation

Medical Physics, 2010-06, Vol.37 (6), p.3129-3129

Elbakri, I

2010

Link zum Volltext

Verfügbarkeit prüfen

A follow-up study on subjective quality of life for elderly persons with dementia using the Japanese version of Dementia Quality of Life Instrument (JDQoL)

Nippon Ronen Igakkai Zasshi. Japanese Journal of Geriatrics, 2006/07/25, Vol.43(4), pp.485-491

2006

Link zum Volltext

Verfügbarkeit prüfen

JDQL: A framework for Java Static Analysis

Proceedings of the 9th India Software Engineering Conference, 2016, p.136-140

2016

Link zum Volltext

Verfügbarkeit prüfen

JDQ

A Dictionary of Abbreviations, 2011

Burt Vance

1, 2011

Link zum Volltext

Verfügbarkeit prüfen

Temperature and doping dependence of normal state spectral properties in a two-orbital model for ferropnictides

Physics letters. A, 2016-04, Vol.380 (18-19), p.1648-1657

2016

Link zum Volltext

Verfügbarkeit prüfen

New tenants fill JDQ Building

Messenger inquirer, 2019-01-12

2019

Link zum Volltext

Verfügbarkeit prüfen

Facelift near for iconic JDQ building to be renovated

Messenger inquirer, 2017-07-05

2017

Link zum Volltext

Verfügbarkeit prüfen

Iconic engineering firm JDQ closing doors

Messenger inquirer, 2016-11-30

2016

Link zum Volltext

Verfügbarkeit prüfen

Environmental Belief Systems: United States, Brazil, and Mexico

Journal of cross-cultural psychology, 1999-01, Vol.30 (1), p.122-128

1999

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 2.525

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(1.839)
Mit Volltextzugriff
(2.330)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

11 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(1.062)
Physical Sciences
(683)
Physics
(361)
Mathematics
(341)
Derivatives
(339)
Technology
(290)
Life Sciences & Biomedicine
(200)
Exact Sciences And Technology
(151)
Engineering
(129)
Mathematics And Statistics
(103)
Physics, Multidisciplinary
(103)
Humans
(102)
Mathematics, Applied
(102)
Computer Science
(98)
Algorithms
(85)
Volatility
(81)
Science & Technology - Other Topics
(80)
Social Sciences
(76)
Physics, Mathematical
(75)
Mathematical Analysis
(74)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(32)
... seit 30 Tagen
(9)

Menü

Weitere Dienste

Einstellungen

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRASG12C for the Treatment of Solid Tumors

KontRASt-02: A Phase III Trial Investigating the Efficacy and Safety of the KRASG12C Inhibitor JDQ443 vs. Docetaxel in Patients with Previously Treated, Locally Advanced or Metastatic, KRAS G12C-Mutated NSCLC

KontRASt-01 Update: Safety and Efficacy of JDQ443 in KRAS G12C-Mutated Solid Tumors Including Non-Small Cell Lung Cancer (NSCLC)

A Phase II Trial of JDQ443 in KRAS G12C-Mutated NSCLC with PD-L1 Expression <1% or PD-L1 Expression ≥1% and an STK11 Co-Mutation

A phase II trial of JDQ443 in KRAS G12C -mutated NSCLC with PD-L1 expression <1% or PD-L1 expression ≥1% and an STK11 co-mutation

KontRASt-01 update: Safety and efficacy of JDQ443 in KRAS G12C -mutated solid tumors including non-small cell lung cancer (NSCLC)

KontRASt-02: A phase III trial investigating the efficacy and safety of the KRAS G12C inhibitor JDQ443 vs docetaxel in patients with previously treated, locally advanced or metastatic, KRAS G12C -mutated NSCLC

JDQ443, a Structurally Novel, Pyrazole-Based, Covalent Inhibitor of KRAS G12C for the Treatment of Solid Tumors

MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors

Abstract LBA038: KontRASt: A Phase Ib/II, open-label, multi-center, dose-escalation study of JDQ443 in patients with advanced solid tumors harboring the KRAS G12C mutation

Abstract P124: JDQ443, a covalent irreversible inhibitor of KRAS G12C, exhibits a novel binding mode and demonstrates potent anti-tumor activity and favorable pharmacokinetic properties in preclinical models

Discovery, Preclinical Characterization, and Early Clinical Activity of JDQ443, a Structurally Novel, Potent, and Selective Covalent Oral Inhibitor of KRASG12C

Abstract CT048: A Phase II trial of JDQ443 in KRAS G12C- mutated NSCLC with PD-L1 expression <1% or PD-L1 expression≥1% and an STK11 co-mutation

EN1-5. KontRASt-01 : A Phase Ib/II, dose-escalation study of JDQ443 in patients with KRAS G12C+ solid tumors

Abstract CT033: KontRASt-01: A phase Ib/II, dose-escalation study of JDQ443 in patients (pts) with advanced, KRAS G12C-mutated solid tumors

Abstract 4026: JDQ443, a covalent inhibitor of KRASG12C with a novel binding mode, shows broad antitumor activity in KRASG12C preclinical models as a single agent and in combination with inhibitors of SHP2, MEK or CDK4/6

SU‐GG‐I‐121: JDQE: A User‐Friendly ImageJ Plugin for DQE Calculation

A follow-up study on subjective quality of life for elderly persons with dementia using the Japanese version of Dementia Quality of Life Instrument (JDQoL)

JDQL: A framework for Java Static Analysis

JDQ

Temperature and doping dependence of normal state spectral properties in a two-orbital model for ferropnictides

New tenants fill JDQ Building

Facelift near for iconic JDQ building to be renovated

Iconic engineering firm JDQ closing doors

Environmental Belief Systems: United States, Brazil, and Mexico

Suchergebnisse filtern